We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are ...

Fintel reports that on January 22, 2025, Stifel initiated coverage of Edgewise Therapeutics (NasdaqGS:EWTX) with a Hold ...

BOULDER, Colo. - Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease treatment ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced key changes ...

Paul Matteis, an analyst from Stifel Nicolaus, has initiated a new Hold rating on Edgewise Therapeutics (EWTX).Invest with Confidence: Follow ...

Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has “very ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was the target of a significant growth in short interest during ...

So notwithstanding the buoyant share price, we think it's well worth asking whether Edgewise Therapeutics' cash burn is too risky. In this report, we will consider the company's annual negative free ...

The exosome therapies market is expected to experience significant growth due to increased interest in regenerative medicine, cancer treatments, and drug delivery systems. Leading Indications ...

Longer-term Phase 1 data expected to be presented at a medical meeting in 2025, following interim data presented in November 2024 demonstrating SPY001 was well tolerated with a half-life of >90 days, ...

CIRCA Scientific is pleased to announce the launch of its innovative CrossWisetm RF Transseptal Access System, designed to ...